Caspase-Independent Regulated Necrosis Pathways as Potential Targets in Cancer Management

Regulated necrosis is an emerging type of cell death independent of caspase. Recently, with increasing findings of regulated necrosis in the field of biochemistry and genetics, the underlying molecular mechanisms and signaling pathways of regulated necrosis are gradually understood. Nowadays, there...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in oncology Vol. 10; p. 616952
Main Authors: Lou, Jianyao, Zhou, Yunxiang, Feng, Zengyu, Ma, Mindi, Yao, Yihan, Wang, Yali, Deng, Yongchuan, Wu, Yulian
Format: Journal Article
Language:English
Published: Switzerland Frontiers Media S.A 16-02-2021
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Regulated necrosis is an emerging type of cell death independent of caspase. Recently, with increasing findings of regulated necrosis in the field of biochemistry and genetics, the underlying molecular mechanisms and signaling pathways of regulated necrosis are gradually understood. Nowadays, there are several modes of regulated necrosis that are tightly related to cancer initiation and development, including necroptosis, ferroptosis, parthanatos, pyroptosis, and so on. What's more, accumulating evidence shows that various compounds can exhibit the anti-cancer effect inducing regulated necrosis in cancer cells, which indicates that caspase-independent regulated necrosis pathways are potential targets in cancer management. In this review, we expand the molecular mechanisms as well as signaling pathways of multiple modes of regulated necrosis. We also elaborate on the roles they play in tumorigenesis and discuss how each of the regulated necrosis pathways could be therapeutically targeted.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
This article was submitted to Cancer Molecular Targets and Therapeutics, a section of the journal Frontiers in Oncology
Reviewed by: Lidia Hernandez, National Institutes of Health (NIH), United States; Kamini Singh, Memorial Sloan Kettering Cancer Center, United States
These authors have contributed equally to this work
Edited by: Christina M. Annunziata, National Cancer Institute (NCI), United States
ISSN:2234-943X
2234-943X
DOI:10.3389/fonc.2020.616952